Effect of Mustadi Yapana Basti Punarnavadi Ghanavati Veerataradi Ghanavati Trikantakadi Ghanavati in Chronic Kidney Disease

Phase 2/3

Not yet recruiting

• Conditions: Chronic kidney disease, stage 2 (mild). Ayurveda Condition: MUTRAGHATAH, (2) ICD-10 Condition: N189||Chronic kidney disease, unspecified. Ayurveda Condition: CKD,

• Registration Number: CTRI/2023/02/050137
• Lead Sponsor: Dr Ashwini Sajjanavar

Brief Summary

The present study entitled THREE ARM RANDOMIZED COMPARATIVE CLINICAL STUDY TO EVALUATE THE COMBINED EFFECT OF MUSTADI YAPANA BASTI FOLLOWED BY PUNARNAVADI GHANAVATI VEERATARADI GHANAVTI AND TRIKANTAKADI GHANAVATI is to be conducted at Ayurveda Mahavidyalaya Hubli and BLDEA’S AVS Ayurveda Mahavidyalaya Vijayapur. This study is mainly focussed on the management of Chronic Kidney Disease and for the betterment of the patients through Ayurvedic intervention.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-01-04
• Last Update Posted: 2023-02-27

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Diagnosed cases of Chronic Kidney Disease Patients.
• ➢ Subjects who are fit for Bastikarma.
• ➢ Subjects having classical common signs and symptoms Gaurava,Anavasthita utseda,Siratanutwa,Salomaharsha,Angavivarnata,Sashoolamutrata,Raktamootrata.
• ➢ Subjects with classical symptoms of Chronic Kidney Disease having clinical features like oedema,pruritis, generalized weakness, nausea.
• ➢ Stages 1, 2 and 3 Glomerular Filtration Rate (30-ml/min per 1.73m2 ) ➢ Microalbuminuria( ACR- 30 to 300mg/g ≥3 months) ➢ Mild hypertension(<130/80MMHG) ➢ Patients aged between 20-70years.
• ➢ Patients of either sex will be taken for study.

Exclusion Criteria

• Patients of Congenital Renal Diseases like Autosomal dominant and Recessive Polycystic Kidney disease, Congenital Nephrotic syndrome (Finnish type), Alport’s syndrome, Fabry‘s disease and Juvenile Nephronopthisis.
• ➢ Subjects who are on dialysis.
• ➢ Uncontrolled Dm.(HBA1C ≥7) ➢ Pregnant women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ALPAMUTRATA PADASHOTHA	30days

Secondary Outcome Measures

Name	Time	Method
SERUM CREATININE GFR LEVELS	30DAYS

Trial Locations

Locations (2)

AYURVEDA MAHAVIDYALAYA HUBLI; 🇮🇳 Dharwad, KARNATAKA, India

BLDEAs AVS Ayurveda Mahavidyalaya, Hospital and Research centre, Vijayapura-586109; 🇮🇳 Bijapur, KARNATAKA, India

AYURVEDA MAHAVIDYALAYA HUBLI

🇮🇳Dharwad, KARNATAKA, India

DR ASHWINI SAJJANAVAR

Principal investigator

7406737888

dr.ashwini.sajjan@gmail.com